Tender detail
Supply of Adagrasib under the B.6 drug programme
Summary
The Institute of Tuberculosis and Lung Diseases is procuring the medicinal product Adagrasib for treatment under the B.6 drug programme, covering small-cell and non-small-cell cancer.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.